The settlement includes licensing Sanvar to one of India's largest drug makers Ranbaxy Laboratories for the markets of India, Bangladesh and Nepal. License agreements were also made with EMS Sigma Farma for Brazil, Tzamal Bio-Pharma for Israel and LG Life Sciences for the Korean market.
Debiopharm continues to seek partnerships in other territories, including Europe where the first international filing was submitted in July in France.
Salix Pharmaceuticals licensed the exclusive rights to Sanvar for the US, where Debiopharm expects to file for marketing approval in the first quarter of 2007, after completion of a phase III clinical trial.
“These partnerships demonstrate the value that Sanvar can add to a growing portfolio of late-stage compounds,” said Loic Maurel, president and CEO of the Debiopharm Group Canadian subsidiary.
Debiopharm Group is a global independent biopharmaceutical development company specializing in oncology and serious medical conditions.